Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) is now available.
China Resources Pharmaceutical Group Ltd. has entered into new Framework Loan Agreements for the period from January 1, 2026, to December 31, 2028, with CRI and CR Holdings, both of which are connected entities to the company. These agreements, which replace the expiring 2023 agreements, are part of the company’s ongoing financial arrangements and are subject to reporting and annual review requirements but do not require independent shareholder approval due to the size of the transactions.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
YTD Price Performance: -16.89%
Average Trading Volume: 14,735,023
Technical Sentiment Signal: Sell
Current Market Cap: HK$28.96B
For an in-depth examination of 3320 stock, go to TipRanks’ Overview page.